Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05438537

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Upper Tract Urothelial Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Prince of Wales Hospital

Hong Kong

Location status: Recruiting

Location contact

Jeremy Yuen-Chun TEOH, FRCS(Ed)

CONTACT

[email protected]

35052625

About this study

Although Upper Tract Urothelial Carcinoma (UTUC) is relatively uncommon, the incidence rate is increasing. There are many controversies and limitations in the management of Upper Tract Urothelial cancer.

In this study, investigators would like to establish a local registry for upper tract urothelial cancer to facilitate the collection of clinical information and outcomes of upper tract urothelial cancer management, and to collect blood, urine and tumour tissue samples to investigate for new diagnostic and therapeutic agents. Hopefully, our registry can provide information regarding the epidemiology, natural history, and treatment outcomes of upper tract urothelial cancer in Hong Kong.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male patients > 18 years old
  • Patients who has presence of UTUC and pending for surgery
  • Patients who has history of UTUC with any intervention performed

Exclusion criteria

  • Patients fail to provide informed consent

Treatment and study plan

Primary outcomes

  1. Long-term survival

    Time frame: 10 years

    Long-term survival

Secondary outcomes

  1. Recurrence rate of UTUC

    Time frame: 10 years

    Recurrence rate of UTUC

  2. Progression rate of UTUC

    Time frame: 10 years

    Progression rate of UTUC

  3. Complications

    Time frame: 10 years

    Complications are assessed by medical record and on patient follow up

Study contacts

Contact information is provided by the study sponsor or research team.

Jeremy Yuen-Chun TEOH, FRCS(Ed)

CONTACT

[email protected]

3505-2625

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Jun 30, 2022
Registry last updated
Jan 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.